Tianjin Medical University Cancer Institute And Hospital

This study tests a personalized, high-dose radiation treatment called SBRT for people with early-stage non-small cell lung cancer who cannot have surgery or choose not to. The goal is to see if this precise radiation can keep the tumor under control and help patients live longer …

This study tests a combination of two drugs, cadonilimab and regorafenib, in 30 adults with advanced liver cancer that has not responded to at least one prior therapy. The goal is to see if the combination can shrink tumors or slow disease progression, while monitoring side effec…

This study tests a combination of three drugs (oral etoposide, anlotinib, and envafolimab) as a first treatment for elderly patients with extensive small cell lung cancer. The goal is to see if this approach can delay cancer growth and improve survival. Thirty participants will r…

This early-phase study tests a new cell treatment (GK01) combined with an immunotherapy drug (PD-1 antibody) in 15 adults with advanced solid tumors that have spread or come back. The main goal is to check safety and how the body handles the treatment, while also looking at wheth…

This study tests a combination of three drugs—fruquintinib, an immunotherapy (checkpoint inhibitor), and an oral chemotherapy (TAS-102)—in people with advanced colorectal cancer that has not responded to standard second-line therapy. About 106 participants will receive the combo …

This study tests whether adding an immunotherapy drug (treprizumab) to standard chemotherapy before surgery can improve outcomes for people with advanced head and neck cancer. About 122 participants will be randomly assigned to receive either the combination or chemotherapy alone…

This study looks at medical records from 400 older adults (age 60+) with Hodgkin lymphoma in China. Researchers are collecting information on patients' health, lab results, treatments, and survival to create a tool that helps doctors predict how the disease will progress. The goa…

This study looked back at medical records of 800 adults with liver cancer that could not be removed by surgery. All patients received a drug called lenvatinib, often combined with other treatments. The goal was to see how many lived for at least 3 years and how safe the treatment…